Skip to main content
SpringerLink
Log in

Mesenchymal Stem Cells as Immune Modulators in VCA

  • Chapter
  • First Online:
The Science of Reconstructive Transplantation

Part of the book series: Stem Cell Biology and Regenerative Medicine ((STEMCELL))

  • 683 Accesses

Abstract

In addition to their widely publicized regenerative properties, mesenchymal stem cells (MSCs) also function as powerful immunomodulatory cells. They have broad impact on several critical features of both the innate and adaptive immune response that makes them attractive agents for use in clinical transplantation to decrease or eliminate the need for systemic lifelong immunosuppression. Preclinical studies in both solid organ and vascularized composite allotransplantation have demonstrated a definitive therapeutic potential to modulate the inflammatory milieu to suppress rejection, improve the host response to foreign antigens, and promote the generation of tolerogenic cell types. Although the clinical data are in its infancy, there is significant evidence that MSCs can modulate the recipient immune response to an allograft and facilitate peripheral tolerance. Herein, we discuss these novel properties of MSCs, their specific immunomodulatory functions on effector cells of the immune system, and their potential role in shaping a new paradigm in the approach to transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105:1815–22.

    CAS  PubMed  Google Scholar 

  2. Aksu AE, Horibe E, Sacks J, Ikeguchi R, Breitinger J, Scozio M, Unadkat J, Feili-Hariri M. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol. 2008;127:348–58.

    CAS  PubMed  Google Scholar 

  3. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, Mcintosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42–8.

    PubMed  Google Scholar 

  4. Benichou G, Tocco G. The road to transplant tolerance is paved with good dendritic cells. Eur J Immunol. 2013 Mar;43(3):584–8.

    Google Scholar 

  5. Bernardo ME, Ball LM, Cometa AM, Roelofs H, Zecca M, Avanzini MA, Bertaina A, Vinti L, Lankester A, Maccario R, Ringden O, Le Blanc K, Egeler RM, Fibbe WE, Locatelli F. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2011;46:200–7.

    CAS  PubMed  Google Scholar 

  6. Bianco P. Back to the future: moving beyond "mesenchymal stem cells";. J Cell Biochem. 2011;112:1713–21.

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Bianco P, Robey PG, Simmons PJ. 2008. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2:313–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  8. Bianco P, Cao X, Frenette PS, Mao JJ, Robey PG, Simmons PJ, Wang CY. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med. 2013;19:35–42.

    PubMed Central  CAS  PubMed  Google Scholar 

  9. Brandacher G, Margreiter R, Fuchs D. Implications of IFN-gamma-mediated tryptophan catabolism on solid organ transplantation. Curr Drug Metab. 2007;8:273–82.

    CAS  PubMed  Google Scholar 

  10. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–50.

    CAS  PubMed  Google Scholar 

  11. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98:1076–84.

    CAS  PubMed  Google Scholar 

  12. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, Cavinato RA, Todeschini M, Solini S, Sonzogni A, Perico N, Remuzzi, G. Noris, M. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol. 2008;181:3933–46.

    CAS  PubMed  Google Scholar 

  13. Casiraghi F, Azzollini N, Todeschini M, Cavinato RA, Cassis P, Solini S, Rota C, Morigi M, Introna M, Maranta R, Perico N, Remuzzi, G. Noris, M. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant. 2012;12:2373–83.

    CAS  PubMed  Google Scholar 

  14. Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant. 2013;18:51–8.

    CAS  PubMed  Google Scholar 

  15. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP, Anegon I, Cuturi MC. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood. 2007;110:3691–4.

    CAS  PubMed  Google Scholar 

  16. Chang EI, Bonillas RG, El-Ftesi S, Ceradini DJ, Vial IN, Chan DA, Michaels JT, Gurtner GC. Tissue engineering using autologous microcirculatory beds as vascularized bioscaffolds. FASEB J. 2009;23:906–15.

    PubMed Central  CAS  PubMed  Google Scholar 

  17. Chen W, Li M, Cheng H, Yan Z, Cao J, Pan B, Sang W, Wu Q, Zeng L, Li Z, Xu K. Overexpression of the mesenchymal stem cell Cxcr4 gene in irradiated mice increases the homing capacity of these cells. Cell Biochem Biophys. 2013;28:28.

    Google Scholar 

  18. Deng W, Han Q, Liao L, You S, Deng H, Zhao RC. Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol. 2005;24:458–63.

    CAS  PubMed  Google Scholar 

  19. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002;99:3838–43.

    CAS  PubMed  Google Scholar 

  20. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes. 2009;58:1797-06

    Google Scholar 

  21. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, Cantos C, Jorgensen C, Noel D. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007;25:2025–32.

    CAS  PubMed  Google Scholar 

  22. Eggenhofer E, Renner P, Soeder Y, Popp FC, Hoogduijn MJ, Geissler EK, Schlitt HJ, Dahlke MH. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol. 2011;25:141–7.

    CAS  PubMed  Google Scholar 

  23. El Haj AJ, Glossop JR, Sura HS, Lees MR, Hu B, Wolbank S, Van Griensven M, Redl H, Dobson J. An in vitro model of mesenchymal stem cell targeting using magnetic particle labelling. J Tissue Eng Regen Med. 2012. DOI:10.1002/term.1636

    Google Scholar 

  24. Eltzschig HK, Eckle T. Ischemia and reperfusion–from mechanism to translation. Nat Med. 2011;17:1391–401.

    CAS  PubMed  Google Scholar 

  25. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 2007;110:91–100.

    CAS  PubMed  Google Scholar 

  26. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett. 2008;115:50–8.

    CAS  PubMed  Google Scholar 

  27. English K, French A, Wood KJ. Mesenchymal stromal cells: facilitators of successful transplantation? Cell Stem Cell. 2010;7:431–42.

    CAS  PubMed  Google Scholar 

  28. English K, Wood KJ. Mesenchymal stromal cells in transplantation rejection and tolerance. Cold Spring Harb Perspect Med. 2013;3:a015560.

    PubMed Central  PubMed  Google Scholar 

  29. Friedenstein AJ, Piatetzky S, II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol. 1966;16:381–90.

    CAS  PubMed  Google Scholar 

  30. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968;6:230–47.

    CAS  PubMed  Google Scholar 

  31. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17:331–40.

    CAS  PubMed  Google Scholar 

  32. Gatti S, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, Tetta C, Camussi G. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011;26:1474–83.

    CAS  PubMed  Google Scholar 

  33. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory t-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation. 2010;90:1312–20

    Google Scholar 

  34. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W, Bartholomew A, Garcia B, Wang H. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant. 2009;9:1760–72.

    CAS  PubMed  Google Scholar 

  35. Gjorgieva D, Zaidman N, Bosnakovski D. Mesenchymal stem cells for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov. 2013;8:310–8.

    CAS  PubMed  Google Scholar 

  36. Hannoush EJ, Sifri ZC, Elhassan IO, Mohr AM, Alzate WD, Offin M, Livingston DH. Impact of enhanced mobilization of bone marrow derived cells to site of injury. J Trauma. 2011;71:283–9; discussion 289–91.

    PubMed  Google Scholar 

  37. Hara Y, Stolk M, Ringe J, Dehne T, Ladhoff J, Kotsch K, Reutzel-Selke A, Reinke P, Volk HD, Seifert M. In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transplant Int. 2011;24:1112–23.

    Google Scholar 

  38. Hare JM, Fishman JE, Gerstenblith G, Difede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, Mcniece IK, Heldman AW. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369–79.

    CAS  PubMed  Google Scholar 

  39. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and Il-1 alpha. J Cell Physiol. 1996;166:585–92.

    CAS  PubMed  Google Scholar 

  40. Heidt S, Segundo DS, Chadha R, Wood KJ. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant. 2010;15: 456–61.

    PubMed Central  PubMed  Google Scholar 

  41. Hoogduijn MJ, Dor FJ. Mesenchymal stem cells in transplantation and tissue regeneration. Front Immunol. 2011;2:84.

    PubMed Central  PubMed  Google Scholar 

  42. Hoogduijn MJ, Roemeling-Van Rhijn M, Korevaar SS, Engela AU, Weimar W, Baan CC. Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies. Hum Gene Ther. 2011;22:1587–91.

    CAS  PubMed  Google Scholar 

  43. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS, Keating A. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy. 2005;7:393–5.

    CAS  PubMed  Google Scholar 

  44. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature. 1984;307:168–70.

    CAS  PubMed  Google Scholar 

  45. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK, Dahlke MH. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation. 2006;81:1589–95.

    PubMed  Google Scholar 

  46. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;418:41–9.

    CAS  PubMed  Google Scholar 

  47. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4:206–16.

    CAS  PubMed  Google Scholar 

  48. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012;10;709–16.

    CAS  PubMed  Google Scholar 

  49. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24:1294–301.

    CAS  PubMed  Google Scholar 

  50. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol. 2008;8:290–301.

    CAS  PubMed  Google Scholar 

  51. Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation. 2008;86:889–94.

    CAS  PubMed  Google Scholar 

  52. Kim YH, Wee YM, Choi MY, Lim DG, Kim SC, Han DJ. Interleukin (il)-10 induced by cd11b(+) cells and il-10-activated regulatory t cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med. 2011;17:697–08

    Google Scholar 

  53. Kim EJ, Kim N, Cho SG. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med. 2013;45:e2.

    PubMed Central  PubMed  Google Scholar 

  54. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004a;94:678–85.

    CAS  PubMed  Google Scholar 

  55. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004b;109:1543–9.

    CAS  PubMed  Google Scholar 

  56. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006a;24:386–98.

    CAS  PubMed  Google Scholar 

  57. Krampera M, Pasini A, Pizzolo G, Cosmi L, Romagnani S, Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol. 2006b;6:435–41.

    CAS  PubMed  Google Scholar 

  58. Kroemer A, Edtinger K, Li XC. The innate natural killer cells in transplant rejection and tolerance induction. Curr Opin Organ Transplant. 2008;13:339–43.

    PubMed  Google Scholar 

  59. Kuo YR, Goto S, Shih HS, Wang FS, Lin CC, Wang CT, Huang EY, Chen CL, Wei FC, Zheng XX, Lee WP. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation. 2009;87:1769–77.

    PubMed  Google Scholar 

  60. Kuo YR, Chen CC, Goto S, Lee IT, Huang CW, Tsai CC, Wang CT, Chen CL. Modulation of immune response and T-cell regulation by donor adipose-derived stem cells in a rodent hind-limb allotransplant model. Plast Reconstr Surg. 2011a;128:661e–72e.

    Google Scholar 

  61. Kuo YR, Chen CC, Shih HS, Goto S, Huang CW, Wang CT, Chen CL, Wei FC. Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plast Reconstr Surg. 2011b;127:569–79.

    CAS  PubMed  Google Scholar 

  62. Kuo YR, Chen CC, Shih HS, Goto S, Huang CW, Wang CT, Chen CL, Wei FC. Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plast Reconstr Surg. 2011c;127:569–79.

    CAS  PubMed  Google Scholar 

  63. Kuo YR, Chen CC, Goto S, Huang YT, Wang CT, Tsai CC, Chen CL. Immunomodulatory effects of bone marrow-derived mesenchymal stem cells in a swine hemi-facial allotransplantation model. PLoS One. 2012;7:e35459.

    PubMed Central  CAS  PubMed  Google Scholar 

  64. Kuzmina LA, Petinati NA, Parovichnikova EN, Lubimova LS, Gribanova EO, Gaponova TV, Shipounova IN, Zhironkina OA, Bigildeev AE, Svinareva DA, Drize NJ, Savchenko VG. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease-A phase II study. Stem Cells Int. 2012;968213.

    PubMed Central  PubMed  Google Scholar 

  65. Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation. 2005;79:505–14.

    PubMed  Google Scholar 

  66. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003a;31:890–6.

    CAS  PubMed  Google Scholar 

  67. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003b;57:11–20.

    CAS  PubMed  Google Scholar 

  68. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579–86.

    CAS  PubMed  Google Scholar 

  69. Li FR, Wang XG, Deng CY, Qi H, Ren LL, Zhou HX. Immune modulation of co-transplantation mesenchymal stem cells with islet on t and dendritic cells. Clin Exp Immunol. 2010;161:357–63

    Google Scholar 

  70. Liechty KW, Mackenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, Marshak DR, Flake AW. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000;6:1282–6.

    CAS  PubMed  Google Scholar 

  71. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, Mazzinghi B, Maggi L, Pasini A, Lisi V, Santarlasci V, Consoloni L, Angelotti ML, Romagnani P, Parronchi P, Krampera M, Maggi E, Romagnani S, Annunziato F. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells. 2008;26:279–89.

    CAS  PubMed  Google Scholar 

  72. Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzon IM, Nepomnaschy I, Costa H, Canones C, Raiden S, Vermeulen M, Geffner JR. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PloS One. 2010;5:e9252.

    PubMed Central  PubMed  Google Scholar 

  73. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, Koc ON. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004;33:597–604.

    CAS  PubMed  Google Scholar 

  74. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229:176–85.

    CAS  PubMed  Google Scholar 

  75. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5:1260–5.

    CAS  PubMed  Google Scholar 

  76. Mcrae M, Ham M, Soares M, Wilson S, Lotfi P, Lalezarzadeh F, Ojo C, Saadeh P, Ceradini D. Ex vivo mesenchymal stem cell therapy protects vascular networks from ischemia reperfusion injury. Plast Reconstr Surg. 2013;131:105. 10.1097/01.prs.0000430081.33685.43.

    Google Scholar 

  77. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma'ayan A, Enikolopov GN, Frenette PS. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:829–34.

    PubMed Central  CAS  PubMed  Google Scholar 

  78. Michaels JV, Levine JP, Hazen A, Ceradini DJ, Galiano RD, Soltanian H, Gurtner GC. Biologic brachytherapy: ex vivo transduction of microvascular beds for efficient, targeted gene therapy. Plast Reconstr Surg. 2006;118:54–65. 10.1097/01.prs.0000220466.27521.22.

    CAS  PubMed  Google Scholar 

  79. Muguruma Y, Yahata T, Miyatake H, Sato T, Uno T, Itoh J, Kato S, Ito M, Hotta T. Ando K. Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood. 2006;107:1878–87.

    CAS  PubMed  Google Scholar 

  80. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol. 2010;264:171–9.

    CAS  PubMed  Google Scholar 

  81. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110:3499–506.

    CAS  PubMed  Google Scholar 

  82. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A, Tolosa E, Hoberg M, Anderl J, Aicher WK, Weller M, Wick W, Platten M. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells. 2009;27:909–19.

    CAS  PubMed  Google Scholar 

  83. Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Marasa M, Golay J, Noris M, Remuzzi G. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol. 2011;6:412–22.

    PubMed Central  PubMed  Google Scholar 

  84. Perico N, Casiraghi F, Gotti E, Introna M, Todeschini M, Cavinato RA, Capelli C, Rambaldi A, Cassis P, Rizzo P, Cortinovis M, Noris M, Remuzzi G. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transplant Int. 2013;26(9):867–78.

    CAS  Google Scholar 

  85. Pittenger MF. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–7.

    CAS  PubMed  Google Scholar 

  86. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004;95:9–20.

    CAS  PubMed  Google Scholar 

  87. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O, Charbord P, Domenech J. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells. 2004;25:1737–45.

    Google Scholar 

  88. Popp FC, Eggenhofer E, Renner P, Slowik P, Lang SA, Kaspar H, Geissler EK, Piso P, Schlitt HJ, Dahlke MH. Mesenchymal stem cells can induce long-term acceptance of solid organ allografts in synergy with low-dose mycophenolate. Transplant Immunol. 2008;20:55–60.

    CAS  Google Scholar 

  89. Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V, Schnitzbauer AA, Hutchinson J, Deans R, Ladenheim D, Graveen CA, Zeman F, Koller M, Hoogduijn MJ, Geissler EK, Schlitt HJ, Dahlke MH. Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation–a phase I study (Misot-I). J Transl Med. 2011;9:124.

    PubMed Central  PubMed  Google Scholar 

  90. Potian JA, Aviv H, Ponzio NM, Harrison JS, Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol. 2003;171:3426–34.

    CAS  PubMed  Google Scholar 

  91. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20:14–20.

    PubMed Central  CAS  PubMed  Google Scholar 

  92. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L, Pistoia V. Human mesenchymal stem cells inhibit neutrophil apoptosis: A model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008;26:151–62

    Google Scholar 

  93. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141–50.

    CAS  PubMed  Google Scholar 

  94. Roemeling-Van Rhijn M, Weimar W, Hoogduijn MJ. Mesenchymal stem cells. Curr Opin Organ Transplant. 2012;17:55–62.

    PubMed  Google Scholar 

  95. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, Bianco P. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell. 2007;131:324–36.

    CAS  PubMed  Google Scholar 

  96. Satija NK, Gurudutta GU, Sharma S, Afrin F, Gupta P, Verma YK, Singh VK, Tripathi RP. Mesenchymal stem cells: molecular targets for tissue engineering. Stem Cells Dev. 2007;16:7–23.

    CAS  PubMed  Google Scholar 

  97. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007;109:228–34.

    CAS  PubMed  Google Scholar 

  98. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787–95.

    PubMed Central  CAS  PubMed  Google Scholar 

  99. Siemionow M, Klimczak A. Basics of immune responses in transplantation in preparation for application of composite tissue allografts in plastic and reconstructive surgery: part I. Plast Reconstr Surg. 2008;121:4e–12e.

    Google Scholar 

  100. Soares M, Low Y, Hwang L, Ham M, Ezeamuzie O, Saadeh P, Ceradini D. Tolerizing allografts with ex-vivo MSC immunotherapy. Plast Reconstr Surg. 2012;130:51. 10.1097/01.prs.0000416148.24037.3d.

    Google Scholar 

  101. Soares MA, Low Y, Ham M, Lalezarzadeh F, Wilson S, Ojo C, Lotfi P, Saadeh P, Ceradini D. Indoleamine-2,3-dioxygenase is critical to mesenchymal stem cell-based allograft tolerization. Plast Reconstr Surg. 2013;131:89. 10.1097/01.prs.0000430057.82105.aa.

    Google Scholar 

  102. Solari MG, Srinivasan S, Boumaza I, Unadkat J, Harb G, Garcia-Ocana A, Feili-Hariri M. Marginal mass islet transplantation with autologous mesenchymal stem cells promotes long-term islet allograft survival and sustained normoglycemia. J Autoimmun. 2009;32:116–24

    Google Scholar 

  103. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111:1327–33.

    CAS  PubMed  Google Scholar 

  104. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 2009;113:6576–83.

    CAS  PubMed  Google Scholar 

  105. Steinert AF, Rackwitz L, Gilbert F, Noth U, Tuan RS. Concise review: the clinical application of mesenchymal stem cells for musculoskeletal regeneration: current status and perspectives. Stem Cells Transl Med. 2012;1:237–47.

    PubMed Central  CAS  PubMed  Google Scholar 

  106. Tan J, Wu W, Xu X, Liao L, Zheng F, Messinger S, Sun X, Chen J, Yang S, Cai J, Gao X, Pileggi A, Ricordi C. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA. 2012;307:1169–77.

    CAS  PubMed  Google Scholar 

  107. Tatara R, Ozaki K, Kikuchi Y, Hatanaka K, Oh I, Meguro A, Matsu H, Sato K, Ozawa K. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy. 2011;13:686–94.

    CAS  PubMed  Google Scholar 

  108. Toledano Furman NE, Lupu Haber Y, Bronshtein T, Kaneti L, Letko N, Weinstein E, Baruch L, Machluf M. Reconstructed stem cell nano-ghosts: a natural tumor targeting platform. Nano Lett. 2013;20:20.

    Google Scholar 

  109. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003;75:389–97.

    CAS  PubMed  Google Scholar 

  110. Tyndall A, Walker UA, Cope A, Dazzi F, De Bari C, Fibbe W, Guiducci S, Jones S, Jorgensen C, Le Blanc K, Luyten F, Mcgonagle D, Martin I, Bocelli-Tyndall C, Pennesi G, Pistoia V, Pitzalis C, Uccelli A, Wulffraat N, Feldmann M. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther. 2007;9:301.

    PubMed Central  PubMed  Google Scholar 

  111. Uccelli A, Moretta L, Pistoia V. Immunoregulatory function of mesenchymal stem cells. Eur J Immunol. 2006;36:2566–73.

    CAS  PubMed  Google Scholar 

  112. Unutmaz D, Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype. PloS One. 2010;5:e10088.

    Google Scholar 

  113. Van Raemdonck D, Neyrinck A, Rega F, Devos T, Pirenne J. Machine perfusion in organ transplantation: a tool for ex-vivo graft conditioning with mesenchymal stem cells? Curr Opin Organ Transplant. 2013;18:24–33.

    Google Scholar 

  114. Vanecek V, Zablotskii V, Forostyak S, Ruzicka J, Herynek V, Babic M, Jendelova P, Kubinova S, Dejneka A, Sykova E. Highly efficient magnetic targeting of mesenchymal stem cells in spinal cord injury. Int J Nanomed. 2012;7:3719–30.

    CAS  Google Scholar 

  115. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W, Ho AD. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005;33:1402–16.

    CAS  PubMed  Google Scholar 

  116. Wang Y, Zhang A, Ye Z, Xie H, Zheng S. Bone marrow-derived mesenchymal stem cells inhibit acute rejection of rat liver allografts in association with regulatory T-cell expansion. Transplant Proc. 2009;41:4352–6.

    CAS  PubMed  Google Scholar 

  117. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6:93–106.

    CAS  PubMed  Google Scholar 

  118. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012;12:417–30.

    CAS  PubMed  Google Scholar 

  119. Wu GD, Bowdish ME, Jin YS, Zhu H, Mitsuhashi N, Barsky LW, Barr ML. Contribution of mesenchymal progenitor cells to tissue repair in rat cardiac allografts undergoing chronic rejection. J Heart Lung Transplant. 2005;24:2160–9.

    PubMed  Google Scholar 

  120. Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ. The role of macrophages in allograft rejection. Transplantation. 2005;80:1641–7.

    PubMed  Google Scholar 

  121. Xu DM, Yu XF, Zhang D, Zhang MX, Zhou JF, Tan PH, Ding YC. Mesenchymal stem cells differentially mediate regulatory t cells and conventional effector t cells to protect fully allogeneic islet grafts in mice. Diabetologia. 2012;55:1091–02

    Google Scholar 

  122. Yu X, Lu C, Liu H, Rao S, Cai J, Liu S, Kriegel AJ, Greene AS, Liang M, Ding X. Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PloS One. 2013;8(5):e62703.

    PubMed Central  CAS  PubMed  Google Scholar 

  123. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, Contag CH, Negrin RS. Inhibition of cd4+cd25+ regulatory t-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108:390–9

    Google Scholar 

  124. Zhou HP, Yi DH, Yu SQ, Sun GC, Cui Q, Zhu HL, Liu JC, Zhang JZ, Wu TJ. Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc. 2006;38:3046–51.

    CAS  PubMed  Google Scholar 

  125. Zonta S, De Martino M, Bedino G, Piotti G, Rampino T, Gregorini M, Frassoni F, Dal Canton A, Dionigi P, Alessiani M. Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial? Transplant Proc. 2010;42:1336–40.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Reconstructive Plastic Surgery, New York University School of Medicine New York University School of Medicine, 305 E 33rdStreet, 10016, New York, NY, USA

    Daniel J. Ceradini MD & Marc A. Soares MD

Authors
  1. Daniel J. Ceradini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc A. Soares MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel J. Ceradini MD .

Editor information

Editors and Affiliations

  1. Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    Gerald Brandacher

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ceradini, D., Soares, M. (2015). Mesenchymal Stem Cells as Immune Modulators in VCA. In: Brandacher, G. (eds) The Science of Reconstructive Transplantation. Stem Cell Biology and Regenerative Medicine. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2071-6_17

Download citation

Publish with us

Policies and ethics

Search

Navigation